Abstract About one half of malignant peripheral nerve sheath tumors (MPNST) have Neurofibromin 1 (NF1) mutations. NF1 is a tumor suppressor gene essential for negative regulation of RAS signaling. Survival for MPNST patients is poor and we sought to identify an effective combination therapy. Starting with the mTOR inhibitors rapamycin and everolimus, we screened for synergy in 542 FDA approved compounds using MPNST cells with a native NF1 loss in both alleles. We further analyzed the cell cycle and signal transduction. In vivo growth effects of the drug combination with local radiation therapy (RT) were assessed in MPNST xenografts. The synergistic combination of mTOR inhibitors with bortezomib yielded a reduction in MPNST cell proliferation. The combination of mTOR inhibitors and bortezomib also enhanced the antiproliferative effect of radiation in vitro. In vivo, the combination of mTOR inhibitor (everolimus) and bortezomib with RT decreased tumor growth and proliferation, and augmented apoptosis. The combination of approved mTOR and proteasome inhibitors with radiation showed a significant reduction of tumor growth in an animal model and should be investigated and optimized further for MPNST therapy.
Introduction
Malignant peripheral nerve sheath tumors (MPNSTs) are an aggressive soft-tissue sarcoma and about 50 % of MPNSTs arise in Neurofibromatosis Type 1 patients (NF1). NF1 patients have 8-13 % lifetime risk of developing a MPNST. Despite aggressive treatment, MPNST has a high rate of recurrence and distant metastases. The 5-year survival rate ranges from 39 to 60 % [1] [2] [3] . These tumors have a poor clinical prognosis, despite efforts to find better targeted therapy [4] .
Neurofibromin 1 (NF1) is a tumor suppressor gene essential for negative regulation of RAS protein activity and is the most frequently mutated gene in MPNSTs [5, 6] . Loss of NF1 up-regulates PI3K/Akt/Mammalian target of rapamycin (mTOR) signaling and sensitizes cells to mTOR inhibitors [7] . Overexpression of mTOR downstream signaling components are observed in MPNST human samples and are associated with poor prognosis in MPNST patients [8, 9] . Preclinical data showed an anti-tumoral effect of allosteric inhibitors of mTOR in MPSNT mouse models. However, blocking mTOR signaling promoted a cytostatic rather than cytotoxic effect [10] .
Combinatorial targeted therapy has been previously tested in preclinical MPNST models. Johansson et al. observed that the mTOR inhibitor everolimus combined with doxorubicin did not reduce MPNST tumor growth in vivo. Everolimus plus erlotinib, an EGFR inhibitor, slightly reduced growth when compared with single treatment in a xenograft MPNST model [11] . Recently, the combination of the mTOR inhibitor rapamycin and HSP90 inhibitors resulted in tumor regression in MPNST transgenic mice, through a mechanism that involved endoplasmatic reticulum stress and subsequent cell death [12] . Preclinical data showed an antiproliferative effect with HSP90 inhibition in other tumor types and several HSP90 inhibitors are in clinical trials [13, 14] .
In this study, we sought to identify potential combination therapies and test their efficacy in an MPNST preclinical model. We focused on FDA approved drugs to accelerate any possible translational to clinical trials. We first screened 542 inhibitors seeking synergy with rapamycin or everolimus to reduce MPNST cell proliferation. We then tested the drug combination with radiation in vitro and in a preclinical xenograft MPNST model.
Materials and methods
Cell culture, transfection and ionizing radiation Human NF1-associated MPNST cell lines NF90.8 and ST88-14 were provided by Dr Michael Tainsky (Wayne University, Detroit, MI), T265-2C was obtained from Dr Steven Porcelli (Albert Einstein College of Medicine, Bronx, NY), and sNF96.2 was purchased from ATCC (Manassas, VA) [15, 16] . MPNST cells were maintained in RPMI 1640 medium (Sigma) containing 10 % fetal bovine serum (BenchMarck, Gemini Bio-Products, West Sacramento, CA) and 1 % penicillin-streptomycin (Invitrogen Life Technologies, Carlsbad, CA) at 37°C in an humidified 5 % CO 2 atmosphere. MPNST cells were transiently transfected with 10 nM of siRNA duplex mTOR#13 (CCAAAGUCAAUGUGCAGGAUCUUCC CA) or mTOR#19 (GCCAAGACACAGUAGCGAAUG UCAGGG) (Integrated DNA Technology, Coralville, IA) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Non-targeting GFP siRNA (IDT DNA Technologies) was used as control. Cells were irradiated in a Caesium 137 (2.24 Gy/min) radiation source Gammacell 1000 (MDS Nordion, Ottawa, ON, Canada). All compound were purchased from LC Laboratories (LC Laboratories, Woburn, MA), with exception of dichloroacetic acid (Tocris, Ellisville, MO) and dissolved in dimethyl sufoxide (DMSO) (Sigma).
Cell proliferation and drug synergism MPNST cell proliferation was performed using the fluorescence cell-based alamarBlue assay (Invitrogen). Fluorescence was read in Victor-3 automated plate reader (Perkim-Elmer, Turku, Finland), with a 540-nm excitation/ 590-nm emission filter. Half inhibitory concentration (IC 50 ) was calculated using GraphPad Prism 5.0 (Prism, La Jolla, CA) as previously described [17] . Effects of drug combinations were calculated using CompuSyn Software (ComboSyn, Paramus, NJ) [18] .
Drug screening
Cell-based drug screening was assessed by using the NINDS discovery library (National Institute of Neurological Disorders and Stroke) and the Approved Oncology Drug Set III library (National Cancer Institute) (Supplementary Table 1 )-in combination with rapamycin or everolimus, as previously described [19] . NF90.8 cells were seeded (10 3 cells/well) in 96-well black flat-bottom plates, allowed to attach for 24 h, individually treated with libraries compounds (4 lM) and rapamycin or everolimus at 25 % of IC 50 (12.5 and 5 lM, respectively). Cell proliferation was analyzed 72 h after drug exposure using alamarBlue assay (Invitrogen). As a secondary screening dose response curves (with at least nine different concentrations) were generated for each drug and cell proliferation was analyzed by alamarBlue assay. IC 50 was calculated using GraphPad Prism 5.0 (Prism, La Jolla, CA, USA) as described above.
Proteasome activity MPNST cells were seeded at 10 4 cells/well in 96-well plates in triplicate and treated with bortezomib. Chymotrypsin-like activity of the 20S proteasome was determined according to the manufacturer's instructions (ProteasomeGlo, Promega). Luminescence was read in Victor-3 automated plate reader (Perkim-Elmer).
Cell cycle analysis
Cell cycle analysis was performed as previously described [20] . MPNST cells (5 9 10 5 ) were subjected to radiation, seeded in triplicate, and treated with everolimus and bortezomib. After 48 h DNA was stained with propidium iodide (20 lg/mL) (Sigma) and measured in flow cytometer BD Calibur (BD Bioscience, San Jose, CA). Data were analyzed in BD CellQuest Pro software (BD Bioscience); pulse width and pulse area were used to exclude doublets.
Western blot
Total protein lysates were extracted using RIPA buffer (Sigma) containing protease and phosphatase inhibitor cocktails (Thermo Scientific, Rockford, IL) and protein concentration was measured using the BCA protein kit assay (Thermo Scientific). Proteins were separated by 4-12 % SDS-PAGE and blotted in a PVDF membrane (Bio-Rad, Hercules, CA) as previously described [21] . The following primary antibodies were used: mTOR (1:1,000), cleaved PARP (Asp214) (1:1,000), PARP (1:1,000), S6 (1:1,000), pS6 (S240/244) (1:1,000) (Cell Signaling, Danvers, MA), GAPDH (1:1,000) (FL-335), BCL-xL (1:1,000) (S-18) (Santa Cruz Biotechnology, Santa Cruz, CA), BAX (1:1,000) (06-499) (Upstate, Lake Placid, NY), and Actin (1:1,000) (Sigma). The antigen-antibody complexes were visualized using a horseradish peroxidase-conjugated secondary antibody (Invitrogen) and an enhanced chemiluminescence system (Thermo).
Immunohistochemistry
Immunohistochemical (IHC) analysis was performed on formalin-fixed paraffin-embedded sections from blocks of xenograft MPNSTs. Immuno detection of cleaved caspase-3 (1:400) and phospho-70S6K (thr389) (p70S6K) (1:100) (Cell Signaling) expression was performed by an indirect 3-stage immunoenzymatic method as previously described [17] . 2 ) (n = 5). Ten days after tumor implantation local radiotherapy was performed by using the Small Animal Radiation Research Platform (SARRP), which mimics the isocentric external-beam used to deliver imageguided radiotherapy in patients [22] . In brief, a 2.3 mm CT-Spot (Beekley Medical, Bristol, CT) was used to locate the tumor in the microcomputer tomography (CT) system. Next, the tumor was locally subjected to 10 Gy of radiation in a single dose (3-mm 9 3-mm beam) 4 mm below the mouse skin. The first dose of everolimus and bortezomib were administrated 5 h after RT. Dry powder compounds were dissolved in 1 % DMSO and 0.9 % sterile saline and stored in aliquots at -20°C. Tumor volume was determined by caliper measurements once or twice a week according to the following formula: length 9 width 2 9 0.5.
Xenograft MPNST and radiation therapy in vivo

Statistical analysis
The statistical analysis was performed by using GraphPad Prism 5.0 (Prism). The data were expressed as mean ± SD. Two-way ANOVA followed by Tukey tests was used for multiple comparisons. P \ 0.05 was considered as statistically significant.
Results
Screening of 542 approved compounds with mTOR inhibitors identifies anti-proliferative combinations
We first determined the effect of mTOR signaling inhibitors as a single agent. Dose-dependent growth inhibition was observed in MPNST cells treated with either rapamycin or everolimus (Fig. 1a) . As a single agent mTOR inhibitors showed a very broad range of IC 50 values in tumor cell lines without an apparent relation to tumor histotype [23] [24] [25] [26] . Figure 1b shows the IC 50 values in MPNST cells harboring inactivating NF1 mutations. Rapamycin and everolimus mTOR inhibitors strongly decreased pS6 protein expression in NF 90.8 and T265-2C cells (Fig. 1c) . We then tested the combination of mTOR inhibitors with 542 compounds in NF90.8 cells, seeking potential candidates for drug combination (Fig. 1d) Table 3 ). The synergistic combination was verified by using the Chou-Talalay method for drug combination. Although bortezomib at low concentration (1nM) showed moderate synergism or antagonism, higher concentration of bortezomib with a range of concentration of mTOR inhibitors yielded very strong synergism in MPNST cells ( Fig. 2b ; Supplementary Table 4) . Bortezomib as a single agent reduced chymotrypsin-like activity of the 20S proteasome MPNST cells (Supplementary Fig. 1 ).
Synergistic combination of mTOR inhibitors and bortezomib radiosensitizes MPNST cells
Since mTOR inhibition radio-sensitizes soft tumor sarcoma and the currently treatment of MPNST involves RT [4, 27] , we reasoned that mTOR inhibition and bortezomib treatment might enhance the effects of radiation on MPNST cells. A reduction in cell viability after radiation was observed in a dose-dependent manner in all MPNST cells tested ( Supplementary Fig. 2 ). When testing the combination of radiation (12 Gy) with inhibition of mTOR by drugs or siRNA mediated gene silencing, we observed a reduction in MPNST cell proliferation ( Supplementary Figs. 4,  5) . Therefore, we examined the combination of mTOR inhibitors with bortezomib plus radiation in MPNST cells. We tested a lower radiation dose (4 Gy) to determine if we could observe synergism between drugs and radiation in a low dose. The triple treatment was the most effective combination to reduce MPNST cell proliferation (Fig. 3) . To assess whether this growth inhibition induced by drug combination and radiation was associated with cell cycle modulation, we analyzed the cell cycle distribution by flow cytometry. As expected, everolimus as a single agent induces G0/G1 cell cycle arrest. The combination of everolimus and bortezomib plus radiation shows a G2/M arrest and increased SubG1 fraction in MPNST cells (Fig. 4a) . To provide further evidence that the therapy combination modulates apoptosis, we performed a protein expression analysis of apoptosis regulators and cleaved-PARP. BCL-xL expression decreased and BAX protein expression slightly increased in cells treated with the combination of everolimus, bortezomib and radiation in NF90.8 cells. In addition, Western blot analysis showed an increased in cleaved-PARP after radiation treatment in NF90.8 cells (Fig. 4b) .
The combination of mTOR inhibition, bortezomib, and radiation decreases MPNST growth in vivo Encouraged by our in vitro data, we tested if the drug combination with radiation could reduce growth of flank A Fig. 3 The drug combination with radiation further decreases MPNST cell proliferation. a MPNST cells were subjected to radiation (4 Gy) Gammacell 1,000 (2.24 Gy/min; radiation source: Caesium 137 ), treated with bortezomib (5 nM) plus rapamycin at 50 % of IC 50 (25 lM for NF90.8; 21 lM for T265-2C cells and 27 lM for sNF96.2) or everolimus 50 % of IC 50 (10 lM for NF90.8; 9.6 lM for T265-2C cells and 11.8 lM for sNF96.2) and after 96 h cell growth was assessed by alamarBlue assay. * P \ 0.05; ** P \ 0.01; *** P \ 0.0001 MPNST xenografts. A preliminary toxicity test was performed to test if drug combination induces a systemic toxicity. Animals treated with everolimus (1.5 mg/kg) in combination with different concentrations of bortezomib (0.65; 0.95; and 1.3 mg/m 2 ) did not show weight loss ( Supplementary Fig. 5 ), suggesting that the combination of everolimus and bortezomib did not induced obvious systemic toxicity. Therefore, we implanted NF90.8 cells subcutaneously nude mice and treated with radiotherapy and/or drugs. In order to mimic the human doses, the drugs administered in mice were similar to the FDA approved human doses according with body surface mass for bortezomib and body mass for everolimus [28] . In this experiment the combination of everolimus and bortezomib decreased the tumor volume in 38 % when compared with control group, a similar effect was observed in RT mice with a reduction in tumor volume in 43 % when compared with control group. RT combined with everolimus or bortezomib decreased the tumor volume in 63 and 51 %, respectively, when compared with control group. The mice treated with RT?everolimus?bortezomib had the lower mean tumor volume, decreasing 72 % when compared with control group (Fig. 5a, b) . We confirmed the mTOR signaling inhibition in xenograft MPNST model by the immunostaining of phospho-P70S6K (p-P70S6K) expression. The groups treated with the everolimus slightly reduced p-P70S6K expression. In addition, cleaved caspase-3 was increased in all groups subjected to radiation, suggesting that RT predominantly induces apoptosis in xenograft MPNST (Fig. 5c ).
Discussion
The pathological molecular effects that occur after NF1 loss, such as increased mTOR signaling, provide possible opportunities for treating NF1-associated tumors such as MPNSTs [10, 29] . However, a combination approach should be considered during the early stages of therapeutic strategy design to help combat the resistance that quickly develops to single agent targeted therapy. This preclinical investigation of combination therapy for MPNST has as its foundation mTOR inhibition. Our drug screen with mTOR inhibitors identified synergistic compounds that decrease cell proliferation. We further characterized a triple treatment in vitro and in vivo by adding radiation to mTOR inhibitors and the synergistic bortezomib. This combination decreased, but unfortunately did not halt, growth of MPNST flank xenografts. Aberrant activation of mTOR signaling is observed in several types of cancer and currently several drugs targeting mTOR signaling are in clinical tests [30] . mTOR signaling plays a central role in MPNST and it is a reasonable target for this tumor type. However, cancer cells acquire drug resistance against single agent therapy [31] . Therefore, drug combination is often a necessary strategy to overcome drug resistance [30, 32] . In addition, drugs with strong synergy might theoretically improve efficacy and decrease normal cell toxicity by reducing required drug concentrations [33] .
NF1 plays an important role in MPNST tumorigenesis, and drugs that show preferential sensitivity for this mutation have potential clinical utility [34, 35] . Cancer cell lines harboring NF1 mutation are more sensitive to bortezomib, suggesting that the proteasome is a useful target for MPNST associated with the NF1 genetic alteration [35] . The combination of an mTOR inhibitor and bortezomib shows synergistic activity in non-solid tumors cells (mantle lymphoma and B-acute lymphocytic leukemia) and in hepatocellular carcinoma cells [24, 26, 36] . In addition, the combination of temsirolimus, an analogue of rapamycin, with bortezomib in relapsed and refractory multiple myeloma patients showed clinical benefit and manageable adverse effects [37] . Although mTOR inhibitors with bortezomib showed synergy in different tumor types, additional investigation is needed.
The addition of radiation in our combination therapy helped reduce cell growth. Down-regulation of BCL-xL and a slight increased in BAX expression was observed in vitro, suggesting that MPNST apoptosis cell was triggered by the combination therapy. Interestingly, BCLxL is overexpressed in human MPNST samples and NF1 deficiency upregulates BCL-xL in vitro. Furthermore, BCL-xL pharmacological inhibition decreased MPNST cell growth in combination with doxorubicin [38] . Therefore, modulating levels of BCL-xL directly, or by targeting upstream regulators, could be an effective inducer of apoptosis. The induction of apoptosis was confirmed by the increase of cleaved caspase-3 in vivo, suggesting that inhibition of MPNST cell growth is due at least in part to apoptosis. Furthermore, adjuvant local radiotherapy improves control of local disease, while small molecule combinations can reach metastatic disease [3, 39] . In summary, our preclinical study yielded some important insights. First, cell-based screening assay for identification of approved compounds that cooperates to decrease cell proliferation is a potentially valuable tool that could accelerate the translational of a therapy to the clinic. Second, using this approach we identified possible drug combination candidates for MPNST treatment. Finally, pharmacologic and side effects for these drugs are known in human, supporting faster translation to the clinic. These preclinical data support a combination therapy, that might include some or all of the modalities tested here, for possible clinical trials in MPNST patients.
